US 12,303,602 B2
Compositions, methods and uses for thermally stable multi-targeted antigens
Theodore Randolph, Niwot, CO (US); and Robert Garcea, Boulder, CO (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, Denver, CO (US)
Filed by THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, Denver, CO (US)
Filed on Sep. 25, 2023, as Appl. No. 18/372,556.
Application 18/372,556 is a continuation of application No. 17/665,285, filed on Feb. 4, 2022, granted, now 11,806,432.
Application 17/665,285 is a continuation of application No. 16/146,686, filed on Sep. 28, 2018, granted, now 11,273,127, issued on Mar. 15, 2022.
Application 16/146,686 is a continuation in part of application No. 15/309,169, abandoned, previously published as PCT/US2015/029529, filed on May 6, 2015.
Claims priority of provisional application 61/989,365, filed on May 6, 2014.
Prior Publication US 2024/0130973 A1, Apr. 25, 2024
Prior Publication US 2024/0226015 A9, Jul. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/16 (2006.01); A61K 9/19 (2006.01); A61K 39/12 (2006.01); A61K 39/295 (2006.01); A61K 45/06 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 9/19 (2013.01) [A61K 9/1623 (2013.01); A61K 9/1694 (2013.01); A61K 39/12 (2013.01); A61K 39/295 (2013.01); A61K 45/06 (2013.01); C12N 7/00 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55572 (2013.01); C12N 2710/20034 (2013.01); C12N 2710/20063 (2013.01); C12N 2710/20071 (2013.01)] 23 Claims
 
1. An essentially dried immunogenic composition comprising:
a single broad-spectrum multi-targeted antigen complex of two or more different pathogens or serotypes, wherein the single complex comprises at least two assembled subunits of the two or more different pathogens and wherein the at least two assembled subunits of the two or more different pathogens are selected from the group consisting of: human papilloma virus (HPV) serotypes, multi-peptide cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) vaccine, Plasmodium falciparum multiple-antigen peptide vaccines, PnuBioVax (PBV multi-antigen), serotype-independent prophylactic vaccine against S. pneumoniae disease, ALVAC (2), melanoma multi-antigen complex, bacterial backed complexes, flavivirus antigenic complexes, and alphavirus antigenic complexes
one or more aluminum salt adjuvant;
one or more non-reducing disaccharide agents selected from the group consisting of trehalose, sucrose, or a combination thereof;
one or more volatile salts, wherein the one or more volatile salts are selected from the group consisting of one or more of ammonium acetate, ammonium formate, triethylammonium acetate, triethylammonium formate, triethylammonium carbonate, trimethylamine acetate, trimethylamine formate, trimethylamine carbonate, pyridinal acetate and pyridinal formate, or combinations thereof; and
wherein the essentially dried immunogenic composition excludes mannitol.